Ervogastat

Cat. No.: 0225LY-0726

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, HPLC, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Ervogastat is a well-tolerated and powerful inhibitor of DGAT2 that reduces hepatic triglycerides and steatosis in cases of non-alcoholic steatohepatitis (NASH).

Synonym: 2186700-33-2; Ervogastat; 2-(5-((3-Ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-((3S)-oxolan3-yl)pyrimidine-5-carboxamide; 5-Pyrimidinecarboxamide, 2-(5-((3-ethoxy-2-pyridinyl)oxy)-3-pyridinyl)-N-((3S)-tetrahydro-3-furanyl)-; 2-[5-(3-ethoxypyridin-2-yl)oxypyridin-3-yl]-N-[(3S)-oxolan-3-yl]pyrimidine-5-carboxamide; (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide; 2-(5-(3-ethoxypyridin-2-yl)oxypyridin-3-yl)-N-((3S)-oxolan-3-yl)pyrimidine-5-carboxamide

CAS No.: 2186700-33-2

Compound CID: 134262752

Formula: C₂₁H₂₁N₅O₄

Formula Weight: 407.42

Specification

Relative Density: 1.36 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Ervogastat can be used in non-alcoholic steatohepatitis (NASH) research to evaluate the dual inhibition of DGAT2 and its effect on liver fat.